Lokelma الاتحاد الأوروبي - الأيسلاندية - EMA (European Medicines Agency)

lokelma

astrazeneca ab - járn sirkon cyclosilicate - blóðkalíumlækkun - Öll önnur lækningavörur - lokelma er ætlað fyrir meðferð hyperkalaemia í fullorðinn sjúklingar.

Ytracis الاتحاد الأوروبي - الأيسلاندية - EMA (European Medicines Agency)

ytracis

cis bio international - yttrium (90y) chloride - radionuclide imaging - greining geislavirkja - aðeins má nota til geislamerktar flutningsfrumeindanna sem hafa verið sérstaklega þróuð og leyfð til geislamerktar með þessu radionuklíði. radiopharmaceutical precursor - not intended for direct application to patients.

Bevespi Aerosphere الاتحاد الأوروبي - الأيسلاندية - EMA (European Medicines Agency)

bevespi aerosphere

astrazeneca ab - glycopyrronium, formoterol fumarate dihydrate - lungnasjúkdómur, langvarandi hindrandi - formóteróli og þannig brómíð - bevespi aerosphere er ætlað sem viðhald berkjuvíkkandi meðferð til að létta einkenni í fullorðinn sjúklinga með langvinn veikindi í lungum (llt).

Zimbus Breezhaler الاتحاد الأوروبي - الأيسلاندية - EMA (European Medicines Agency)

zimbus breezhaler

novartis europharm limited - glycopyrronium bromide, indacaterol (acetate), mometasone furoate - astma - lyf til veikindi öndunarvegi sjúkdómum, - maintenance treatment of asthma in adults whose disease is not adequately controlled.

Pedmarqsi الاتحاد الأوروبي - الأيسلاندية - EMA (European Medicines Agency)

pedmarqsi

fennec pharmaceuticals (eu) limited - sodium thiosulfate - ear diseases; ototoxicity - Öll önnur lækningavörur - pedmarqsi is indicated for the prevention of ototoxicity induced by cisplatin chemotherapy in patients 1 month to < 18 years of age with localised, non-metastatic, solid tumours.

Sugammadex Mylan الاتحاد الأوروبي - الأيسلاندية - EMA (European Medicines Agency)

sugammadex mylan

mylan ireland limited - sugammadex sodium - taugakerfi - Öll önnur lækningavörur - reversal of neuromuscular blockade induced by   rocuronium or vecuronium in adults. for the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in children and adolescents aged 2 to 17 years.